Petros Pharmaceuticals, Inc. announced its partnership with Idea Evolver (IE), a Technology platform for Rx-to-OTC switches and digital pharmaceutical launch solutions. The partnership will focus on developing an application to help facilitate the technology element for the Company's prescription to OTC switch for its erectile dysfunction drug STENDRA® (avanafil). The application will be developed using IE's proprietary Rx-to-OTC platform, CodeScripts.

Idea Evolver has worked with multiple large healthcare organizations to provide various technology solutions. The company also took part in the only technology-enabled prescription to OTC switch clinical study published (Nissen et.al., JACC Vol. 78, No.

11, 2021, September 14, 2021:114-1123), which is also known as an Actual Use Trial for rosuvastatin (Crestor), which was included in an application to the FDA for OTC approval. The development of the technology, which Petros intends to use for future studies as well as in practice, will be based on provided branding, consumer research, and behavior analysis. The collaboration between Petros and Idea Evolver will focus on incorporating Idea Evolver's experience with human factors and usability engineering into the application's design, as well as developing artificial intelligence components.